News & Updates

The use of single-dose psilocybin offers potential safety and efficacy in patients with severe treatment-resistant depression (TRD), a study has shown.

A population-based cohort study in Finland has revealed that clozapine initiation after a first-episode schizophrenia relapse is associated with a lower risk of second relapse compared with continuation with the same antipsychotic or switching to another non-clozapine oral antipsychotic. These findings challenge current guidelines that recommend clozapine as a third-line treatment.

Cognitive remediation (CR) plus transcranial direct current stimulation (tDCS) is effective in slowing cognitive decline in older adults with remitted major depressive disorder (MDD), mild cognitive impairment (MCI), or both, according to a randomized clinical trial. 

The use of clozapine appears to slightly increase the risk of haematological malignancy (HM) among patients with schizophrenia compared with olanzapine use, suggests a study.